More patients had Fuhrman grade 3–4 RCC in the post-treatment hypoalbuminemia group (63.2%, 24/38) than in the post-treatment normal albumin level group (28.1%, 41/146; P < 0.001) (Table 1). This evidence concerns the gene ALB and renal cell carcinoma.